Home  »  Companies   »  Cyclacel Pharmaceuticals Inc.’s (CYCC) 0.68%...

Cyclacel Pharmaceuticals Inc.’s (CYCC) 0.68% Increase Justifies A Second Look

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) concluded the trading at $1.48 on Wednesday, June 29 with a rise of 0.68% from its closing price on previous day.

Taking a look at stock we notice that its last check on previous day was $1.47 and 5Y monthly beta was reading 1.21 with its price kept floating in the range of $1.39 and $1.63 on the day. Considering stock’s 52-week price range provides that CYCC hit a high price of $6.41 and saw its price falling to a low level of $1.05 during that period. Over a period of past 1-month, stock came adding 22.31% in its value.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored

With its current market valuation of $15.01 million, Cyclacel Pharmaceuticals Inc. is set to declare its quarterly results on Feb 23, 2022 – Feb 28, 2022. Analysts are in estimates of -$0.68 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$2.49 for 2022 with estimates of that growing to -$3.56 in next year. These estimates are suggesting current year growth of -16.40% for EPS and -43.00% growth next year.

In last 7 days, analysts came adjusting their opinions about stock’s EPS with no upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review CYCC stock’s current outlook then short term indicators are assigning it an average of 50% Sell, while medium term indicators are categorizing the stock at an average of 100% Sell. Long term indicators are suggesting an average of 100% Sell for it.

Digging deeper we become aware of the PEG ratio of the CYCC stock which is currently positioned at 0. It further provides that stock’s current price level is 17.98% away from its 20-day simple moving average and is -0.77% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 58.32 while volatility remained at 9.92% over the past week which changes to 9.28% when measuring it over the past month. Beta is valued at 1.19, while measure of average true range or ATR is currently at 0.12.

In comparing Cyclacel Pharmaceuticals Inc. (CYCC)’s stock with other industry players reveals that stock’s current price change of 0.68% and that of -75.74% over the past 12 months is in competing position with that of Eli Lilly and Company (LLY) which saw its stock price raised by 1.69% in the last trading and went through an increase of 40.82% in past 12-month trading. Industry’s another major player CASI Pharmaceuticals Inc. (CASI) has fall -2.73% down in previous session, but over the past year has faced a fall of -81.37%, while Johnson & Johnson (JNJ) was also up 0.03% however its price remained floating in the green at 7.90% over the same period. Cyclacel Pharmaceuticals Inc. has a P/E ratio of 0 against that of Eli Lilly and Company’s 47.93. On the other hand, the S&P 500 Index was down -0.07% in the last trading session while the Dow Jones Industrial closed the session higher at 0.27%.

Having a second look at Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) provides that stock’s average daily trading volume for 3 months was 318.52K. Number of outstanding shares of the stock stood at 9.99 million.

The percentage of outstanding shares held by the insiders is 1.40% while it is 41.00% for the institutional holders. Subtraction of -61.95% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.

Leave a Comment

Your email address will not be published.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]